Baird Maintains Bullish View on Karyopharm Therapeutics (KPTI) Following Positive STORM Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/25/2024
- Futures falter as Meta Platforms weighs on megacaps
- Meta shares dip on softer Q2 revenue guidance, elevated AI spending plans
- Oil steady as US demand concerns balance Middle East conflict risks
- Yen at multi-decade lows, dollar drops before US data
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- Hasbro (HAS) brand strength sees earnings top expectations
- Meta Platforms (META) Tops Q1 EPS by 39c, Offers Guidance
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- Crude Inventory Declined 6.4 Million Barrels Last Week
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
- After-hours movers: Cadence Design Systems, Cleveland-Cliffs, Riot Platforms, and more
Karyopharm Reports Positive Top-Line Phase 2b STORM Results and Reviews the Planned Development Path for Selinexor in Multiple Myeloma
September 6, 2016 7:00 AM EDT
- Selinexor Achieves Promising Response Rates in Patients with Multiple Myeloma, Including 20.8% in Quad-Refractory and 20.0% in Penta-Refractory Disease -
- Expanding Phase 2b STORM Study to Include Approximately 120 Additional Patients with Penta-Refractory Myeloma to Support Seeking Accelerated Approval -
- Plan to Initiate Pivotal Randomized Phase 3 BOSTON Study in early 2017 to Evaluate Selinexor in Combination with Bortezomib and Dexamethasone versus Bortezomib and Dexamethasone in Previously Treated Myeloma Patients -
- Management to Host Conference Call Today at... More
